Among A. baumannii patients, 98% had an overnight hospital stay in the year prior

A study published in Emerging Infectious Diseases investigated the incidence of carbapenem-nonsusceptible Acinetobacter baumannii in the U. S. from 2012 through 2015.

Advertisement

Researchers conducted laboratory-and population-based surveillance in certain areas in Colorado, Georgia, Maryland, Minnesota, New Mexico, New York, Oregon and Tennessee. They collected carbapenem-nonsusceptible A. baumannii cultured from urine or normally sterile sites. They identified 621 cases in 537 patients.

The crude annual incidence was 1.2 cases per 100,000 persons. Among the 598 cases for which complete data were available, 98.7 percent occurred among patients with overnight stays in a hospital during the previous year. Around 84.6 percent occurred in patients who had an indwelling device.

“Although incidence was lower than for other healthcare-associated pathogens, cases were associated with substantial rates of illness and death,” study authors concluded.

More articles on healthcare quality: 
House rejects ‘right-to-try’ bill: 9 things to know
National Institute on Drug Abuse recognizes NYU Langone Health’s Dr. Nathaniel Landau
ECRI Institute ranks 10 top patient safety concerns for 2018

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

The 2 KPIs that drive readmissions — and how hospitals act on them in real time

Tuesday, August 11
1:00 PM - 2:00 PM CDT

Presenter: Nik Rao, Dexur

Advertisement

Next Up in Clinical Leadership & Infection Control

Advertisement

Comments are closed.